Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Status:
Recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back
or not gotten better with treatment. The trial will study whether brentuximab vedotin plus
two drugs works better to treat this type of cancer than the two drugs alone.
Patients will be randomly assigned to get either brentuximab vedotin or placebo. The placebo
will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded,"
patients and their doctors will not know whether a patient gets brentuximab vedotin or
placebo. All patients in the study will get rituximab and lenalidomide. These are drugs that
can be used to treat DLBCL.